Stuart Snyder

Array ( [id] => 10412703 [patent_doc_number] => 20150297713 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-10-22 [patent_title] => 'RSV MUCOSAL VACCINE' [patent_app_type] => utility [patent_app_number] => 14/241596 [patent_app_country] => US [patent_app_date] => 2012-08-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 7678 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14241596 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9081438 [patent_doc_number] => 20130266968 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-10-10 [patent_title] => 'DETECTION OF INFLUENZA VIRUS' [patent_app_type] => utility [patent_app_number] => 13/598230 [patent_app_country] => US [patent_app_date] => 2012-08-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 14325 [patent_no_of_claims] => 39 [patent_no_of_ind_claims] => 35 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13598230 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9970928 [patent_doc_number] => 09017935 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-04-28 [patent_title] => 'HIV-1 latency model for high throughput screening' [patent_app_type] => utility [patent_app_number] => 13/551257 [patent_app_country] => US [patent_app_date] => 2012-07-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 9983 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13551257 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11793200 [patent_doc_number] => 09402891 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-08-02 [patent_title] => 'Norovirus immunogens and related materials and methods' [patent_app_type] => utility [patent_app_number] => 14/124499 [patent_app_country] => US [patent_app_date] => 2012-06-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 10 [patent_no_of_words] => 8990 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14124499 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8476734 [patent_doc_number] => 20120276141 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-11-01 [patent_title] => 'ENV POLYPEPTIDE COMPLEXES AND METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 13/492219 [patent_app_country] => US [patent_app_date] => 2012-06-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 28160 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13492219 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11915419 [patent_doc_number] => 09783594 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-10-10 [patent_title] => 'Human immunodeficiency virus neutralizing antibodies and methods of use thereof' [patent_app_type] => utility [patent_app_number] => 14/118496 [patent_app_country] => US [patent_app_date] => 2012-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 20 [patent_no_of_words] => 34555 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14118496 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9964240 [patent_doc_number] => 09011848 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-04-21 [patent_title] => 'Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereof' [patent_app_type] => utility [patent_app_number] => 13/458964 [patent_app_country] => US [patent_app_date] => 2012-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 10 [patent_no_of_words] => 34740 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 436 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13458964 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9338818 [patent_doc_number] => 20140065601 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-03-06 [patent_title] => 'METHOD AND KIT FOR ESTIMATING HUMAN IMMUNODEFICIENCY VIRUS (HIV) INCIDENCE' [patent_app_type] => utility [patent_app_number] => 14/006688 [patent_app_country] => US [patent_app_date] => 2012-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 15459 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14006688 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11635353 [patent_doc_number] => 09657312 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-05-23 [patent_title] => 'Replication competent pseudo-type retrovirus vector system' [patent_app_type] => utility [patent_app_number] => 14/384687 [patent_app_country] => US [patent_app_date] => 2012-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 26 [patent_no_of_words] => 10916 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14384687 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10155969 [patent_doc_number] => 09187730 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-11-17 [patent_title] => 'Equine rhinitis vaccine' [patent_app_type] => utility [patent_app_number] => 13/417855 [patent_app_country] => US [patent_app_date] => 2012-03-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 36793 [patent_no_of_claims] => 45 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 136 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13417855 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9294537 [patent_doc_number] => 20140038171 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-02-06 [patent_title] => 'RAPID CELL PURIFICATION SYSTEMS' [patent_app_type] => utility [patent_app_number] => 14/004145 [patent_app_country] => US [patent_app_date] => 2012-03-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 9888 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14004145 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10967462 [patent_doc_number] => 20140370494 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-12-18 [patent_title] => 'EXOGENOUS INTERNAL POSITIVE CONTROL' [patent_app_type] => utility [patent_app_number] => 14/001462 [patent_app_country] => US [patent_app_date] => 2012-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9623 [patent_no_of_claims] => 39 [patent_no_of_ind_claims] => 29 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14001462 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8370187 [patent_doc_number] => 20120219577 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-08-30 [patent_title] => 'HIV-1 CLADE A CONSENSUS SEQUENCES, ANTIGENS, AND TRANSGENES' [patent_app_type] => utility [patent_app_number] => 13/398897 [patent_app_country] => US [patent_app_date] => 2012-02-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 39 [patent_figures_cnt] => 39 [patent_no_of_words] => 17189 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13398897 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9280326 [patent_doc_number] => 20140030294 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-01-30 [patent_title] => 'METHODS FOR INCREASING IMMUNE RESPONSES USING AGENTS THAT DIRECTLY BIND TO AND ACTIVATE IRE-1' [patent_app_type] => utility [patent_app_number] => 13/983180 [patent_app_country] => US [patent_app_date] => 2012-02-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 14102 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13983180 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9369859 [patent_doc_number] => 20140079732 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-03-20 [patent_title] => 'COMBINATION VACCINES' [patent_app_type] => utility [patent_app_number] => 13/982131 [patent_app_country] => US [patent_app_date] => 2012-01-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 36 [patent_no_of_words] => 39766 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13982131 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9396150 [patent_doc_number] => 20140093556 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-04-03 [patent_title] => 'Immunological Compositions Against HIV' [patent_app_type] => utility [patent_app_number] => 13/981671 [patent_app_country] => US [patent_app_date] => 2012-01-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 19491 [patent_no_of_claims] => 36 [patent_no_of_ind_claims] => 13 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13981671 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9191401 [patent_doc_number] => 20130330716 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-12-12 [patent_title] => 'METHOD FOR DETERMINING THE TITRE OF VIRUSES BY USING INFECTIOUS STANDARDS' [patent_app_type] => utility [patent_app_number] => 13/990474 [patent_app_country] => US [patent_app_date] => 2011-12-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 6402 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13990474 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11915611 [patent_doc_number] => 09783787 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-10-10 [patent_title] => 'Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3′-UTR of dengue types 1, 2, 3, and 4, or antigenic chimeric dengue viruses 1, 2, 3, and 4' [patent_app_type] => utility [patent_app_number] => 13/305639 [patent_app_country] => US [patent_app_date] => 2011-11-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 19 [patent_no_of_words] => 30962 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 272 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13305639 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9603000 [patent_doc_number] => 20140199682 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-07-17 [patent_title] => 'INFLUENZA NEUTRALIZING AGENTS' [patent_app_type] => utility [patent_app_number] => 13/885786 [patent_app_country] => US [patent_app_date] => 2011-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 35754 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13885786 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8197145 [patent_doc_number] => 20120121634 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-05-17 [patent_title] => 'SOLUBLE PD-1 VARIANTS, FUSION CONSTRUCTS, AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 13/294306 [patent_app_country] => US [patent_app_date] => 2011-11-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 36 [patent_no_of_words] => 16712 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0121/20120121634.pdf [firstpage_image] =>[orig_patent_app_number] => 13294306 [rel_patent_id] =>[rel_patent_doc_number] =>)